Bangshun Pharma files for HKEX listing; two core products targeting JAK2 and BTK, focused on oncology and autoimmune innovative drugs

NewTimeSpace News: On 30 August 2026, Hangzhou Bangshun Pharmaceutical Co., Ltd. filed a listing application with HKEX. Incorporated in 2020, the Company is a commercial-stage biotech company focused on the discovery, development and commercialization of innovative therapies for oncology and autoimmune diseases, aiming to become a sustainable, fully integrated biopharmaceutical company with drug discovery, development and commercialization capabilities.

According to the announcement, the Company has built a pipeline comprising two core products and five preclinical candidates. Core product bezesertinib is a selective JAK2 inhibitor currently under development for multiple indications including myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET); core product CX1440 is a selective Bruton's tyrosine kinase (BTK) inhibitor at the registration-stage clinical phase, currently under development for multiple indications including immune thrombocytopenia (ITP), chronic urticaria (CU) and autoimmune hemolytic anemia (AIHA); and there are five preclinical candidates, CX03, CX12, CX13, CX15 and CX16.

According to Frost & Sullivan, as of the last practicable date, bezesertinib is among the first three approved domestic JAK inhibitors in China for the treatment of MF; in terms of clinical progress, bezesertinib ranks first in China among JAK inhibitors for the treatment of PV and first globally among JAK inhibitors for the treatment of ET. The other core product, CX1440, is among the top three BTK inhibitors globally for the treatment of ITP and among the top two BTK inhibitors globally for the treatment of CU and AIHA.

The Company strategically focuses on building oral small-molecule candidates with broader and more differentiated indication coverage than competitors, aiming to address the high prevalence of hematological malignancies and autoimmune diseases.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.